Pegylated arginine deiminase: a novel anticancer enzyme agent.

Article Details

Citation
Copy to clipboard

Feun L, Savaraj N

Pegylated arginine deiminase: a novel anticancer enzyme agent.

Expert Opin Investig Drugs. 2006 Jul;15(7):815-22.

PubMed ID
16787144 [ View in PubMed
]
Abstract

Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumours, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumours that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Phase I - II trials in patients with melanoma and hepatocellular carcinomas have shown the drug to have antitumour activity and tolerable side effects. Large Phase II trials and randomised, controlled Phase III trials are needed to determine its overall efficacy in the treatment of these malignancies and others.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
ArginineArgininosuccinate synthaseProteinHumans
Unknown
Not AvailableDetails